Anzeige
Mehr »
Login
Freitag, 28.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Jerusalem Post: Eine große Hürde für den CBD-Pharmabereich wurde von InnoCan Pharma eingerissen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9RU ISIN: US47010C6075 Ticker-Symbol: 1JA 
Tradegate
27.01.22
17:45 Uhr
0,670 Euro
+0,035
+5,51 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6250,63527.01.
0,6200,64527.01.

Aktuelle News zur JAGUAR HEALTH Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoJaguar Health, Inc.: Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics367Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS)For SBS, Napo Therapeutics has...
► Artikel lesen
13.01.Jaguar Health plans awareness activities for launch of chemo-related dog drug Canalevia5
13.01. Jaguar Health, Inc.: Jaguar Health Provides Corporate Update and Outlines 2022 Milestones7752021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure...
► Artikel lesen
JAGUAR HEALTH Aktie jetzt für 0€ handeln
12.01.Why Jaguar Health Shares Are Rising2
12.01.JAGX Stock Alert: What Is Going on With Jaguar Health Today?4
12.01.Jaguar Health, Inc.: Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida225Canalevia-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDAU.S. veterinarians, veterinary...
► Artikel lesen
04.01.Jaguar Health, Inc.: Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs338The Canalevia.com website, a resource for veterinarians and dog owners, is now liveCanalevia-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of...
► Artikel lesen
22.12.21Jaguar Health, Inc.: Jaguar Health Shares Comments from FDA's December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs319By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri treeSAN FRANCISCO, CA / ACCESSWIRE...
► Artikel lesen
22.12.21FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs8
21.12.21JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher10
21.12.21Jaguar Health, Inc.: Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA446By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri treeSAN FRANCISCO, CA / ACCESSWIRE...
► Artikel lesen
21.12.21Jaguar Health wins FDA OK for Canalevia in chemotherapy-induced diarrhea in dogs13
21.12.21JAGX, SEAC and EQOS among mid-day movers5
20.12.21Jaguar Health, Inc.: Jaguar Health's Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company's Focus on Rare Diseases & Orphan Drugs261SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics...
► Artikel lesen
13.12.21Jaguar Health, Inc.: European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health's Italian Subsidiary, for Short Bowel Syndrome307The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar HealthSAN...
► Artikel lesen
10.12.21Jaguar Health, Inc. - 8-K, Current Report7
10.12.21Jaguar Health, Inc.: Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Sympo270Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patientsSAN...
► Artikel lesen
09.12.21Jaguar Health (JAGX) Investor Presentation - Slideshow10
06.12.21Jaguar Health, Inc.: Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company's Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)260Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2"SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting...
► Artikel lesen
19.11.21Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients14
Seite:  Weiter >>
106 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,2